Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study).
Stephanie KornKatrin MilgerDirk SkowaschChristian SchulzCordula MohrlangMartin WernitzThomas PaulssonMichael HennigRoland BuhlPublished in: Journal of asthma and allergy (2023)
The GAN registry data confirm the effectiveness of mepolizumab in a real-world setting. Treatment benefits are maintained over time. While the asthma of patients treated in routine practice was more severe, the results observed with mepolizumab are broadly consistent with RCTs.